News | March 11, 2023
Marksans Pharma announces USFDA approval for Famotidine Tablets
Marksans' OTC Famotidine Tablets USP are acid reducers
Marksans' OTC Famotidine Tablets USP are acid reducers
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Marksans Pharma has reported consolidated financial results for the period ended December 31, 2021
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Subscribe To Our Newsletter & Stay Updated
